Global and India Cancer Companion Diagnostic Market Report & Forecast 2024-2034
Published on: 2024-01-04 | No of Pages : 400 | Industry : Medical
Publisher : MRA | Format : PDF
Global and India Cancer Companion Diagnostic Market Report & Forecast 2024-2034
Companion diagnostic (CD) is an in vitro diagnostic technology that can provide information about a patient's therapeutic response to a specific therapeutic drug, helping to identify patient groups who can benefit from a certain therapeutic product, thereby improving treatment prognosis. and reduce health care costs. Additionally, companion diagnostics can help identify patient populations most likely to respond to therapeutic agents. The companion diagnostics market is still in its early stages.
The global Cancer Companion Diagnostic revenue was US$ million in 2022 and is forecast to a readjusted size of US$ million by 2033 with a CAGR of % during the review period (2023-2033).
In India, the Cancer Companion Diagnostic revenue is expected to grow from US$ million in 2022 to US$ million by 2033, at a CAGR of % during the forecast period 2023-2033.
The number of cancer patients is gradually increasing, drug accessibility is improving, and the research and development of targeted drugs and immunotherapy continue to increase. This is the main trend of drug development in the next ten years.
This report focuses on global and India Cancer Companion Diagnostic market, also covers the segmentation data of other regions in regional level and county level.
India is now the world’s most populous country. According to IMF (its July update to its World Economic Outlook), India’s GDP growth is projected at 6.1% in 2023, powered by domestic investment. First and foremost, the key factor in India's rapid economic growth is the huge supply and demand from a large population base. Demand and supply sides working in both directions to support India's economic stability.
India is a market full of opportunities, and the demand for Cancer Companion Diagnostic will continue to grow rapidly in the future.
Global Cancer Companion Diagnostic Scope and Market Size
Cancer Companion Diagnostic market is segmented in regional and country level, by players, by Type and by Application. Companies, stakeholders, and other participants in the global Cancer Companion Diagnostic market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application for the period 2018-2033.
For India market, this report focuses on the Cancer Companion Diagnostic market size by players, by Type and by Application, for the period 2018-2033. The key players include the global and local players, which play important roles in India.
AmoyDx
Novogene
Illumina
Roche
Agilent
Abbott
Thermo Fisher
Qiagen
Guardant Health
Segment by Type
Polymerase Chain Reaction (PCR)
“Next Generation” Sequencing (NGS)
Fluorescence In Situ Hybridization (FISH)
Immunohistochemistry (IHC)
Lung Cancer
Colorectal Cancer
Breast Cancer
Others
By Region
Americas
United States
Canada
Mexico
Brazil
China
APAC (excluding China)
Japan
South Korea
China Taiwan
ASEAN
India
EMEA
Europe
Middle East
Africa
Chapter 1Introduces Cancer Companion Diagnostic definition, global market size, India market size, India percentage in global market. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 2Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3Provides the analysis of various market segments by application, covering the revenue and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4Detailed analysis of Cancer Companion Diagnostic companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger and acquisition information, etc.
Chapter 5Revenue of Cancer Companion Diagnostic in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 6Americas by type, by application and by country revenue for each segment.
Chapter 7EMEA by type, by application and by region, revenue for each segment.
Chapter 8China by type, by application revenue for each segment.
Chapter 9APAC (excluding China) by type, by application and by region, revenue for each segment.
Chapter 10Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Cancer Companion Diagnostic revenue, gross margin and recent development, etc.
Chapter 11Analyst's Viewpoints/Conclusions
The global Cancer Companion Diagnostic revenue was US$ million in 2022 and is forecast to a readjusted size of US$ million by 2033 with a CAGR of % during the review period (2023-2033).
In India, the Cancer Companion Diagnostic revenue is expected to grow from US$ million in 2022 to US$ million by 2033, at a CAGR of % during the forecast period 2023-2033.
The number of cancer patients is gradually increasing, drug accessibility is improving, and the research and development of targeted drugs and immunotherapy continue to increase. This is the main trend of drug development in the next ten years.
This report focuses on global and India Cancer Companion Diagnostic market, also covers the segmentation data of other regions in regional level and county level.
India is now the world’s most populous country. According to IMF (its July update to its World Economic Outlook), India’s GDP growth is projected at 6.1% in 2023, powered by domestic investment. First and foremost, the key factor in India's rapid economic growth is the huge supply and demand from a large population base. Demand and supply sides working in both directions to support India's economic stability.
India is a market full of opportunities, and the demand for Cancer Companion Diagnostic will continue to grow rapidly in the future.
Global Cancer Companion Diagnostic Scope and Market Size
Cancer Companion Diagnostic market is segmented in regional and country level, by players, by Type and by Application. Companies, stakeholders, and other participants in the global Cancer Companion Diagnostic market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application for the period 2018-2033.
For India market, this report focuses on the Cancer Companion Diagnostic market size by players, by Type and by Application, for the period 2018-2033. The key players include the global and local players, which play important roles in India.
By Company
AmoyDx
Novogene
Illumina
Roche
Agilent
Abbott
Thermo Fisher
Qiagen
Guardant Health
Segment by Type
Polymerase Chain Reaction (PCR)
“Next Generation” Sequencing (NGS)
Fluorescence In Situ Hybridization (FISH)
Immunohistochemistry (IHC)
Segment by Application
Lung Cancer
Colorectal Cancer
Breast Cancer
Others
By Region
Americas
United States
Canada
Mexico
Brazil
China
APAC (excluding China)
Japan
South Korea
China Taiwan
ASEAN
India
EMEA
Europe
Middle East
Africa
Chapter Introduction
Chapter 1Introduces Cancer Companion Diagnostic definition, global market size, India market size, India percentage in global market. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 2Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3Provides the analysis of various market segments by application, covering the revenue and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4Detailed analysis of Cancer Companion Diagnostic companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger and acquisition information, etc.
Chapter 5Revenue of Cancer Companion Diagnostic in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 6Americas by type, by application and by country revenue for each segment.
Chapter 7EMEA by type, by application and by region, revenue for each segment.
Chapter 8China by type, by application revenue for each segment.
Chapter 9APAC (excluding China) by type, by application and by region, revenue for each segment.
Chapter 10Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Cancer Companion Diagnostic revenue, gross margin and recent development, etc.
Chapter 11Analyst's Viewpoints/Conclusions
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices